Review
Medicine, General & Internal
Kamila Boszkiewicz, Agnieszka Piwowar, Pawel Petryszyn
Summary: Aromatase inhibitors (AIs) are commonly used as first-line therapy for hormone-dependent breast cancer patients. However, their use is associated with increased risk of cardiovascular events and the development of insulin resistance and diabetes. This meta-analysis found that AIs are associated with a higher risk of cardiovascular events compared to tamoxifen (TAM), but no significant association was found with hypertension, dyslipidemia, hyperglycemia, or weight gain.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Jeong-Ju Yoo, Eun-Ae Jung, Zisun Kim, Bo-Yeon Kim
Summary: The aim of this study was to investigate the cardiovascular side effects of aromatase inhibitor (AI) treatment in breast cancer patients and evaluate the changes in lipid profile during AI treatment. A pooled analysis of 25 studies found that the use of AI may lead to various cardiovascular diseases, with an increased risk of myocardial infarction and ischemic stroke compared to tamoxifen. Furthermore, AI treatment for 6-12 months was associated with reduced HDL-cholesterol levels and increased LDL-cholesterol and total cholesterol. Therefore, a personalized treatment strategy considering individual cardiovascular risk factors is necessary during AI treatment.
Article
Oncology
Maria Sund, Miguel Garcia-Argibay, Hans Garmo, Johan Ahlgren, Anna-Karin Wennstig, Irma Fredriksson, Henrik Lindman, Antonis Valachis
Summary: This study found an increased risk for arrhythmia and acute ischemic heart disease in breast cancer patients treated with AIs for more than four years. This conclusion should be taken into consideration in the risk-benefit assessment of endocrine therapy.
Review
Chemistry, Medicinal
Ankita Sood, Damanpreet Kaur Lang, Rajwinder Kaur, Balraj Saini, Sandeep Arora
Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Review
Oncology
Felice Crocetto, Matteo Ferro, Carlo Buonerba, Luca Bardi, Pasquale Dolce, Luca Scafuri, Benito Fabio Mirto, Antonio Verde, Antonella Sciarra, Biagio Barone, Armando Calogero, Caterina Sagnelli, Gian Maria Busetto, Francesco Del Giudice, Simone Cilio, Guru Sonpavde, Rossella Di Trolio, Giuseppe Luca Della Ratta, Gabriele Barbato, Giuseppe Di Lorenzo
Summary: A meta-analysis found that immune checkpoint inhibitors (ICIs) do not significantly increase the risk of cardiotoxicity, while anti-VEGF agents are associated with increased risk of cardiovascular events. Further research, including real world studies, is needed.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Qiuyan Yu, Yueping Xu, Enguang Yu, Zhufeng Zheng
Summary: The study compared cardiovascular adverse outcomes between breast cancer patients treated with tamoxifen and aromatase inhibitors. It found slightly increased risks of stroke, angina, myocardial infarction, and heart failure for patients receiving aromatase inhibitors, and a slightly increased risk of venous thromboembolism for those treated with tamoxifen, although none of the differences were statistically significant.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Oncology
Matteo Franchi, Roberta Tritto, Luigi Tarantini, Alessandro Navazio, Giovanni Corrao
Summary: For post-menopausal women with estrogen-receptor-positive breast cancer, treatment with aromatase inhibitors reduces disease recurrence and mortality compared to tamoxifen, but it also increases the risk of heart failure and cardiovascular events, especially in patients with existing cardiovascular risk factors. The interdisciplinary collaboration between oncologists and cardiologists is crucial in evaluating the risk/benefit ratio of hormone therapy choice.
Review
Immunology
Maryam Balibegloo, Seyed Aria Nejadghaderi, Mona Sadeghalvad, Alireza Soleymanitabar, Sasan Salehi Nezamabadi, Amene Saghazadeh, Nima Rezaei
Summary: The results indicated that AEs and irAEs caused by ICIs were more common in patients with breast cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Endocrinology & Metabolism
Aya Bassatne, Abir Bou Khalil, Marlene Chakhtoura, Asma Arabi, Catherine Van Poznak, Ghada El-Hajj Fuleihan
Summary: This study suggests a protective effect of antiresorptive drugs on bone mineral density and bone turnover markers in postmenopausal women with non-metastatic breast cancer on aromatase inhibitors (AIs), but the data on fracture risk reduction is still unclear.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Review
Oncology
Nanna Jordt, Kasper Aalbaek Kjaergaard, Reimar W. Thomsen, Signe Borgquist, Deirdre Cronin-Fenton
Summary: Breast cancer and its treatments, particularly tamoxifen therapy, are associated with an elevated risk of developing type 2 diabetes (T2D). Further research is needed to determine the impact of aromatase inhibitors and chemotherapy on the incidence of T2D after breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Oncology
Xue-Ying Zhu, Zhong Li, Cong Chen, Ru-Li Feng, Bai-Ru Cheng, Ruo-Yi Liu, Rui-Ting Wang, Li Xu, Yue Wang, Xin Tao, Peng Zhao
Summary: This study evaluated the effects of physical therapies on psychosomatic symptoms and quality of life in breast cancer patients. Results suggested that acupuncture significantly reduced pain intensity, while exercise might improve quality of life in these patients. However, no significant improvements were found in psychosomatic symptoms such as anxiety, sleep disturbance, and fatigue.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Eileen Rillamas-Sun, Marilyn L. Kwan, Carlos Iribarren, Richard Cheng, Romain Neugebauer, Jamal S. Rana, Mai Nguyen-Huynh, Zaixing Shi, Cecile A. Laurent, Valerie S. Lee, Janise M. Roh, Yuhan Huang, Hanjie Shen, Dawn L. Hershman, Lawrence H. Kushi, Heather Greenlee
Summary: This study investigated the effects of endocrine therapy on cardiovascular disease risk factors in hormone receptor-positive breast cancer survivors. The results suggest that survivors treated with AIs may have a higher risk of developing diabetes, dyslipidemia, and hypertension compared to those not using endocrine therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Biology
Yixi Zhang, Jingyuan Wang, Taobo Hu, Huina Wang, Mengping Long, Baosheng Liang
Summary: This study aimed to investigate the treatment-related adverse events of PD-1 or PD-L1 inhibitors in triple-negative breast cancer (TNBC) patients. The meta-analysis revealed that the incidence of serious immune-related adverse events was low but significantly higher in the PD-1 or PD-L1 inhibitors groups compared to the chemotherapy groups. Non-serious adverse events were also more frequent in the PD-1 or PD-L1 inhibitors groups.
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Havard Soiland, Jurgen Geisler, Tone Hoel Lende, Per Eystein Lonning, Jorn Sagen, Gunnar Mellgren, Bjorg Almas
Summary: This study developed a liquid chromatography-tandem mass spectrometry (MS/MS) method for simultaneous measurement of serum levels of third-generation aromatase inhibitors (AIs) and ultra-low levels of estrogens. The method is highly valuable for studying drug efficacy and compliance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Oncology
Ke Jin, Kun-kai Su, Tong Li, Xia-qing Zhu, Qi Wang, Ren-shan Ge, Zong-fu Pan, Bo-wen Wu, Li-jun Ge, Yi-han zhang, Yi-fan Wang, Guo-fang Shen, Dan-yan Zhu, Chun-sheng Xiang, Lan-juan Li, Yi-jia Lou
CANCER PREVENTION RESEARCH
(2016)
Article
Neurosciences
Ike C. dela Pena, Guofang Shen, Wei-Xing Shi
Article
Neurosciences
Guofang Shen, Feng Han, Wei-Xing Shi
Article
Biochemistry & Molecular Biology
Guofang Shen, Wei-Xing Shi
Summary: Research has shown that methylphenidate and d-amphetamine can promote excitatory states in rat prefrontal cortex neurons, potentially through the involvement of norepinephrine. These two medications are commonly used for treating ADHD, but come with adverse effects such as abuse potential and psychomimetic effects. Further understanding of their mechanisms of action may lead to safer treatments for ADHD and new insights into drug addiction and psychosis.
Review
Neurosciences
Guofang Shen, Qingyi Ma
CURRENT NEUROPHARMACOLOGY
(2020)
Article
Geriatrics & Gerontology
Guofang Shen, Shirley Hu, Zhen Zhao, Lubo Zhang, Qingyi Ma
FRONTIERS IN AGING NEUROSCIENCE
(2020)
Article
Pharmacology & Pharmacy
Ike dela Pena, Guofang Shen, Wei-Xing Shi
Summary: The study found that L-DOPS had effects on the PFC and dopamine neurons similar to drugs used to treat ADHD, and BZ + L-DOPS also improved ADHD-like behaviors in rats.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Guofang Shen, Shirley Hu, Zhen Zhao, Lubo Zhang, Qingyi Ma
Summary: CNP plays a vascular protective role in neonatal brain injury by reducing brain infarct size, decreasing brain edema and IgG extravasation, and protecting BMECs against oxygen-glucose deprivation. The vasculoprotective effect of CNP is mediated by its innate receptors NPR2 and NPR3, indicating a potential therapeutic target for neonatal brain injury.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Guofang Shen, Wei-Xing Shi
Summary: Cortical neurons oscillate between different states during sleep and wakefulness, with D-amphetamine promoting the Up state by affecting dopamine receptors. The effect of D-amphetamine is influenced by both D1 and D2-like receptors, indicating an interdependence between the two. This finding may help explain why L-DOPA lacks significant psychostimulant properties and is ineffective in treating attention-deficit/hyperactivity disorder.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Yong Li, Rui Song, Guofang Shen, Lei Huang, DaLiao Xiao, Qingyi Ma, Lubo Zhang
Summary: In this study, it was discovered that miR210 regulates neuroinflammatory response induced by ischemic stroke through repression of TET2 in the adult mouse brain. Inhibition of miR210 reduced ischemic stroke-induced neuroinflammatory response, suggesting that miR210 is a potential treatment target for acute brain injury after ischemic stroke.
Article
Multidisciplinary Sciences
Guofang Shen, Kayla Sanchez, Shirley Hu, Zhen Zhao, Lubo Zhang, Qingyi Ma
Summary: This study used a non-invasive 3D ultrasound imaging approach to evaluate the changes of cerebral blood flow (CBF) after hypoxic-ischemic encephalopathy (HIE) and explored its correlation with HI-induced brain infarct in mice. The results showed that CBF reduction is an indicator for neonatal HI brain injury, and 3D ultrasound imaging is a useful non-invasive approach for assessing HI brain injury in mice.
Review
Pharmacology & Pharmacy
Guofang Shen, Kao Tang Ying Moua, Kathryn Perkins, Deron Johnson, Arthur Li, Peter Curtin, Wei Gao, Jeannine S. McCune
Summary: Sirolimus, a mTOR inhibitor, is prescribed to treat various diseases in children. Precision dosing through therapeutic drug monitoring is the current standard of care, but variability in pharmacokinetics, toxicity, and effectiveness still exists. Model-informed precision dosing and pharmacogenomic tools should be further explored. Point-of-care quantitation of sirolimus using dried blood spots is not recommended.
FRONTIERS IN PHARMACOLOGY
(2023)